Compare · ELV vs TLSI
ELV vs TLSI
Side-by-side comparison of Elevance Health Inc. (ELV) and TriSalus Life Sciences Inc. (TLSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and TLSI operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $92.91B, about 386.9x TLSI ($240.1M).
- TLSI has been more active in the news (6 items in the past 4 weeks vs 3 for ELV).
- ELV has more recent analyst coverage (23 ratings vs 7 for TLSI).
- Company
- Elevance Health Inc.
- TriSalus Life Sciences Inc.
- Price
- -
- -
- Market cap
- $92.91B
- $240.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 3
- 6
- Recent ratings
- 23
- 7
ELV
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest ELV
- SEC Form 4 filed by Elevance Health Inc.
- Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026
- Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- EVP & Chief Legal Officer Wessling Erin M covered exercise/tax liability with 349 shares, decreasing direct ownership by 5% to 7,230 units (SEC Form 4)
- EVP & Chief HR Officer Craig Ryan R covered exercise/tax liability with 144 shares, decreasing direct ownership by 2% to 6,530 units (SEC Form 4)
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
Latest TLSI
- SEC Form 4 filed by TriSalus Life Sciences Inc.
- SEC Form 4 filed by TriSalus Life Sciences Inc.
- SEC Form 4 filed by TriSalus Life Sciences Inc.
- SEC Form 4 filed by TriSalus Life Sciences Inc.
- TriSalus Life Sciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
- H.C. Wainwright initiated coverage on TriSalus Life Sciences with a new price target
- TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
- SEC Form 10-Q filed by TriSalus Life Sciences Inc.
- TriSalus Life Sciences Reports Second Quarter 2026 Results